Copyright Reports & Markets. All rights reserved.

Global Nuclear Receptor ROR-Gamma Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Nuclear Receptor ROR-Gamma Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Nuclear Receptor ROR-Gamma Market Size Growth Rate by Product
      • 1.4.2 VPR-66
      • 1.4.3 INV-17
      • 1.4.4 GSK-2981278
      • 1.4.5 BBI-6000
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Nuclear Receptor ROR-Gamma Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Nuclear Receptor ROR-Gamma Market Size
      • 2.1.1 Global Nuclear Receptor ROR-Gamma Revenue 2014-2025
      • 2.1.2 Global Nuclear Receptor ROR-Gamma Sales 2014-2025
    • 2.2 Nuclear Receptor ROR-Gamma Growth Rate by Regions
      • 2.2.1 Global Nuclear Receptor ROR-Gamma Sales by Regions
      • 2.2.2 Global Nuclear Receptor ROR-Gamma Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Nuclear Receptor ROR-Gamma Sales by Manufacturers
      • 3.1.1 Nuclear Receptor ROR-Gamma Sales by Manufacturers
      • 3.1.2 Nuclear Receptor ROR-Gamma Sales Market Share by Manufacturers
      • 3.1.3 Global Nuclear Receptor ROR-Gamma Market Concentration Ratio (CR5 and HHI)
    • 3.2 Nuclear Receptor ROR-Gamma Revenue by Manufacturers
      • 3.2.1 Nuclear Receptor ROR-Gamma Revenue by Manufacturers (2014-2019)
      • 3.2.2 Nuclear Receptor ROR-Gamma Revenue Share by Manufacturers (2014-2019)
    • 3.3 Nuclear Receptor ROR-Gamma Price by Manufacturers
    • 3.4 Nuclear Receptor ROR-Gamma Manufacturing Base Distribution, Product Types
      • 3.4.1 Nuclear Receptor ROR-Gamma Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Nuclear Receptor ROR-Gamma Product Type
      • 3.4.3 Date of International Manufacturers Enter into Nuclear Receptor ROR-Gamma Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Nuclear Receptor ROR-Gamma Sales by Product
    • 4.2 Global Nuclear Receptor ROR-Gamma Revenue by Product
    • 4.3 Nuclear Receptor ROR-Gamma Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Nuclear Receptor ROR-Gamma Breakdown Data by End User

    6 North America

    • 6.1 North America Nuclear Receptor ROR-Gamma by Countries
      • 6.1.1 North America Nuclear Receptor ROR-Gamma Sales by Countries
      • 6.1.2 North America Nuclear Receptor ROR-Gamma Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Nuclear Receptor ROR-Gamma by Product
    • 6.3 North America Nuclear Receptor ROR-Gamma by End User

    7 Europe

    • 7.1 Europe Nuclear Receptor ROR-Gamma by Countries
      • 7.1.1 Europe Nuclear Receptor ROR-Gamma Sales by Countries
      • 7.1.2 Europe Nuclear Receptor ROR-Gamma Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Nuclear Receptor ROR-Gamma by Product
    • 7.3 Europe Nuclear Receptor ROR-Gamma by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Nuclear Receptor ROR-Gamma by Countries
      • 8.1.1 Asia Pacific Nuclear Receptor ROR-Gamma Sales by Countries
      • 8.1.2 Asia Pacific Nuclear Receptor ROR-Gamma Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Nuclear Receptor ROR-Gamma by Product
    • 8.3 Asia Pacific Nuclear Receptor ROR-Gamma by End User

    9 Central & South America

    • 9.1 Central & South America Nuclear Receptor ROR-Gamma by Countries
      • 9.1.1 Central & South America Nuclear Receptor ROR-Gamma Sales by Countries
      • 9.1.2 Central & South America Nuclear Receptor ROR-Gamma Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Nuclear Receptor ROR-Gamma by Product
    • 9.3 Central & South America Nuclear Receptor ROR-Gamma by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Nuclear Receptor ROR-Gamma by Countries
      • 10.1.1 Middle East and Africa Nuclear Receptor ROR-Gamma Sales by Countries
      • 10.1.2 Middle East and Africa Nuclear Receptor ROR-Gamma Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Nuclear Receptor ROR-Gamma by Product
    • 10.3 Middle East and Africa Nuclear Receptor ROR-Gamma by End User

    11 Company Profiles

    • 11.1 4SC AG
      • 11.1.1 4SC AG Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 4SC AG Nuclear Receptor ROR-Gamma Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 4SC AG Nuclear Receptor ROR-Gamma Products Offered
      • 11.1.5 4SC AG Recent Development
    • 11.2 Advinus Therapeutics Ltd.
      • 11.2.1 Advinus Therapeutics Ltd. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Products Offered
      • 11.2.5 Advinus Therapeutics Ltd. Recent Development
    • 11.3 Arrien Pharmaceuticals, LLC
      • 11.3.1 Arrien Pharmaceuticals, LLC Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Products Offered
      • 11.3.5 Arrien Pharmaceuticals, LLC Recent Development
    • 11.4 Aurigene Discovery Technologies Limited
      • 11.4.1 Aurigene Discovery Technologies Limited Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Products Offered
      • 11.4.5 Aurigene Discovery Technologies Limited Recent Development
    • 11.5 Biogen, Inc.
      • 11.5.1 Biogen, Inc. Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Biogen, Inc. Nuclear Receptor ROR-Gamma Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Biogen, Inc. Nuclear Receptor ROR-Gamma Products Offered
      • 11.5.5 Biogen, Inc. Recent Development
    • 11.6 Brickell Biotech, Inc.
      • 11.6.1 Brickell Biotech, Inc. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Products Offered
      • 11.6.5 Brickell Biotech, Inc. Recent Development
    • 11.7 Bristol-Myers Squibb Company
      • 11.7.1 Bristol-Myers Squibb Company Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Products Offered
      • 11.7.5 Bristol-Myers Squibb Company Recent Development
    • 11.8 Celgene Corporation
      • 11.8.1 Celgene Corporation Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Celgene Corporation Nuclear Receptor ROR-Gamma Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Celgene Corporation Nuclear Receptor ROR-Gamma Products Offered
      • 11.8.5 Celgene Corporation Recent Development
    • 11.9 Genentech, Inc.
      • 11.9.1 Genentech, Inc. Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Genentech, Inc. Nuclear Receptor ROR-Gamma Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Genentech, Inc. Nuclear Receptor ROR-Gamma Products Offered
      • 11.9.5 Genentech, Inc. Recent Development
    • 11.10 Genfit SA
      • 11.10.1 Genfit SA Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Genfit SA Nuclear Receptor ROR-Gamma Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Genfit SA Nuclear Receptor ROR-Gamma Products Offered
      • 11.10.5 Genfit SA Recent Development
    • 11.11 GlaxoSmithKline Plc
    • 11.12 Hanmi Pharmaceuticals, Co. Ltd.
    • 11.13 Karo Bio AB
    • 11.14 Lead Pharma Holding B.V.
    • 11.15 Nuevolution AB
    • 11.16 Phenex Pharmaceuticals AG
    • 11.17 Reata Pharmaceuticals, Inc.
    • 11.18 Teijin Pharma Limited
    • 11.19 Visionary Pharmaceuticals, Inc.
    • 11.20 Vitae Pharmaceuticals, Inc.

    12 Future Forecast

    • 12.1 Nuclear Receptor ROR-Gamma Market Forecast by Regions
      • 12.1.1 Global Nuclear Receptor ROR-Gamma Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Nuclear Receptor ROR-Gamma Revenue Forecast by Regions 2019-2025
    • 12.2 Nuclear Receptor ROR-Gamma Market Forecast by Product
      • 12.2.1 Global Nuclear Receptor ROR-Gamma Sales Forecast by Product 2019-2025
      • 12.2.2 Global Nuclear Receptor ROR-Gamma Revenue Forecast by Product 2019-2025
    • 12.3 Nuclear Receptor ROR-Gamma Market Forecast by End User
    • 12.4 North America Nuclear Receptor ROR-Gamma Forecast
    • 12.5 Europe Nuclear Receptor ROR-Gamma Forecast
    • 12.6 Asia Pacific Nuclear Receptor ROR-Gamma Forecast
    • 12.7 Central & South America Nuclear Receptor ROR-Gamma Forecast
    • 12.8 Middle East and Africa Nuclear Receptor ROR-Gamma Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Nuclear Receptor ROR-Gamma Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Nuclear Receptor ROR-Gamma market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Nuclear Receptor ROR-Gamma market based on company, product type, end user and key regions.

      This report studies the global market size of Nuclear Receptor ROR-Gamma in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Nuclear Receptor ROR-Gamma in these regions.
      This research report categorizes the global Nuclear Receptor ROR-Gamma market by top players/brands, region, type and end user. This report also studies the global Nuclear Receptor ROR-Gamma market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      4SC AG
      Advinus Therapeutics Ltd.
      Arrien Pharmaceuticals, LLC
      Aurigene Discovery Technologies Limited
      Biogen, Inc.
      Brickell Biotech, Inc.
      Bristol-Myers Squibb Company
      Celgene Corporation
      Genentech, Inc.
      Genfit SA
      GlaxoSmithKline Plc
      Hanmi Pharmaceuticals, Co. Ltd.
      Karo Bio AB
      Lead Pharma Holding B.V.
      Nuevolution AB
      Phenex Pharmaceuticals AG
      Reata Pharmaceuticals, Inc.
      Teijin Pharma Limited
      Visionary Pharmaceuticals, Inc.
      Vitae Pharmaceuticals, Inc.

      Market size by Product
      VPR-66
      INV-17
      GSK-2981278
      BBI-6000
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Nuclear Receptor ROR-Gamma market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Nuclear Receptor ROR-Gamma market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Nuclear Receptor ROR-Gamma companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Nuclear Receptor ROR-Gamma submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Nuclear Receptor ROR-Gamma are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Nuclear Receptor ROR-Gamma market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now